

# Andy GÃ¶bel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7620979/publications.pdf>

Version: 2024-02-01

24  
papers

507  
citations

759233

12  
h-index

677142

22  
g-index

24  
all docs

24  
docs citations

24  
times ranked

714  
citing authors

#	ARTICLE	IF	CITATIONS
1	Decoding Single Cell Morphology in Osteotropic Breast Cancer Cells for Dissecting Their Migratory, Molecular and Biophysical Heterogeneity. <i>Cancers</i> , 2022, 14, 603.	3.7	5
2	Bone Metastases: From Mechanisms to Treatment. <i>Seminars in Oncology Nursing</i> , 2022, , 151277.	1.5	5
3	The mevalonate pathway in breast cancer biology. <i>Cancer Letters</i> , 2022, 542, 215761.	7.2	5
4	From Pharmacology to Physiology: Endocrine Functions of $\mu$ -Opioid Receptor Networks. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 306-319.	7.1	9
5	The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5078.	4.1	20
6	Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3122-3133.	3.6	10
7	Cholesterol and beyond - The role of the mevalonate pathway in cancer biology. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1873, 188351.	7.4	87
8	Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer. <i>BMC Cancer</i> , 2020, 20, 703.	2.6	22
9	High serum levels of periostin are associated with a poor survival in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 515-524.	2.5	15
10	Evolving functions of Dickkopf-1 in cancer and immunity. <i>Cancer Letters</i> , 2020, 482, 1-7.	7.2	25
11	Dorsomorphin: A novel inhibitor of Dickkopf-1 in breast cancer. <i>Biochemical and Biophysical Research Communications</i> , 2020, 524, 360-365.	2.1	5
12	Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. <i>Cell Death and Disease</i> , 2019, 10, 91.	6.3	66
13	Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients. <i>Journal of Bone Oncology</i> , 2019, 16, 100237.	2.4	3
14	Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1369-1378.	7.0	28
15	Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 737-743.	2.5	8
16	Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 92.	5.0	21
17	Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells. <i>Cancer Letters</i> , 2016, 375, 162-171.	7.2	39
18	Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 623-631.	2.5	20

#	ARTICLE	IF	CITATIONS
19	P38 regulates the Wnt inhibitor Dickkopf-1 in breast cancer. Biochemical and Biophysical Research Communications, 2015, 466, 728-732.	2.1	11
20	Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin. Journal of Bone Oncology, 2014, 3, 18-24.	2.4	9
21	Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. Breast Cancer Research, 2014, 16, R20.	5.0	32
22	Dickkopf-1 as a mediator and novel target in malignant bone disease. Cancer Letters, 2014, 346, 172-177.	7.2	36
23	Zoledronic acid and atorvastatin inhibit $\alpha$ 2 $\beta$ 3-mediated adhesion of breast cancer cells. Journal of Bone Oncology, 2014, 3, 10-17.	2.4	16
24	Regulation of VEGF by mevalonate pathway inhibition in breast cancer. Journal of Bone Oncology, 2013, 2, 110-115.	2.4	10